BrainStorm Cell Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025. The company, focused on developing adult stem cell therapeutics for neurodegenerative diseases, recorded a net loss of approximately $2.9 million for the quarter, a decrease from the net loss of approximately $3.4 million in the same period the previous year. Research and development expenditures increased to $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024. General and administrative expenses also rose to approximately $1.8 million from approximately $1.5 million in the corresponding quarter of the prior year. In addition to financial results, BrainStorm provided a corporate update on its NurOwn® development program. The company announced an IND amendment submission for NurOwn to the U.S. Food and Drug Administration, paving the way for the initiation of a Phase 3b clinical trial. This trial, designed in collaboration with the FDA under a Special Protocol Assessment, aims to confirm the product's efficacy in early-stage ALS patients. Furthermore, BrainStorm's leadership presented biomarker insights at the 2025 ALS Drug Development Summit, emphasizing the relationship between cerebrospinal fluid biomarker pathways and clinical outcomes in ALS treatment.